| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 148 | 2020 | 941 | 12.310 |
Why?
|
| Body Composition | 111 | 2020 | 388 | 7.890 |
Why?
|
| Mobility Limitation | 52 | 2020 | 219 | 5.950 |
Why?
|
| Aged | 383 | 2020 | 10288 | 5.590 |
Why?
|
| Female | 396 | 2020 | 19859 | 4.020 |
Why?
|
| Male | 380 | 2020 | 19091 | 3.940 |
Why?
|
| Obesity | 44 | 2020 | 1158 | 3.940 |
Why?
|
| Muscle Strength | 29 | 2020 | 159 | 3.880 |
Why?
|
| Humans | 446 | 2020 | 31836 | 3.760 |
Why?
|
| Walking | 46 | 2020 | 208 | 3.540 |
Why?
|
| Geriatric Assessment | 57 | 2020 | 390 | 3.340 |
Why?
|
| Vitamin D | 26 | 2018 | 183 | 3.180 |
Why?
|
| Weight Loss | 27 | 2020 | 465 | 3.100 |
Why?
|
| Aged, 80 and over | 132 | 2020 | 3988 | 2.900 |
Why?
|
| Exercise | 40 | 2020 | 663 | 2.860 |
Why?
|
| Vitamin D Deficiency | 15 | 2018 | 89 | 2.850 |
Why?
|
| Mortality | 23 | 2019 | 124 | 2.710 |
Why?
|
| Body Mass Index | 61 | 2019 | 916 | 2.590 |
Why?
|
| Gait | 27 | 2020 | 140 | 2.570 |
Why?
|
| Prospective Studies | 100 | 2020 | 2277 | 2.490 |
Why?
|
| Activities of Daily Living | 30 | 2020 | 257 | 2.350 |
Why?
|
| Sarcopenia | 13 | 2020 | 62 | 2.340 |
Why?
|
| Motor Activity | 27 | 2019 | 325 | 2.340 |
Why?
|
| Heart Failure | 27 | 2018 | 620 | 2.330 |
Why?
|
| Physical Fitness | 16 | 2014 | 131 | 2.300 |
Why?
|
| Geriatrics | 9 | 2020 | 85 | 2.290 |
Why?
|
| Health Status | 39 | 2020 | 397 | 2.260 |
Why?
|
| Interleukin-6 | 37 | 2020 | 251 | 2.250 |
Why?
|
| Risk Factors | 113 | 2020 | 3851 | 2.240 |
Why?
|
| Deglutition | 7 | 2017 | 29 | 2.230 |
Why?
|
| Respiratory Aspiration | 6 | 2017 | 21 | 2.210 |
Why?
|
| Hand Strength | 22 | 2020 | 100 | 2.210 |
Why?
|
| Life Style | 32 | 2020 | 407 | 2.190 |
Why?
|
| Disability Evaluation | 26 | 2020 | 238 | 2.190 |
Why?
|
| European Continental Ancestry Group | 64 | 2020 | 1169 | 2.150 |
Why?
|
| Genome-Wide Association Study | 33 | 2019 | 549 | 2.100 |
Why?
|
| Disabled Persons | 14 | 2020 | 105 | 2.060 |
Why?
|
| Cardiovascular Diseases | 28 | 2020 | 1122 | 2.050 |
Why?
|
| Cohort Studies | 98 | 2020 | 1824 | 2.010 |
Why?
|
| Inflammation | 35 | 2020 | 540 | 2.000 |
Why?
|
| Muscle, Skeletal | 31 | 2019 | 513 | 1.780 |
Why?
|
| Polymorphism, Single Nucleotide | 39 | 2019 | 1067 | 1.760 |
Why?
|
| Adipose Tissue | 24 | 2019 | 345 | 1.760 |
Why?
|
| Frail Elderly | 12 | 2019 | 68 | 1.680 |
Why?
|
| Longitudinal Studies | 51 | 2019 | 771 | 1.630 |
Why?
|
| Follow-Up Studies | 59 | 2020 | 2271 | 1.610 |
Why?
|
| Depression | 17 | 2020 | 442 | 1.570 |
Why?
|
| Life Expectancy | 4 | 2020 | 16 | 1.560 |
Why?
|
| Adiposity | 14 | 2018 | 198 | 1.550 |
Why?
|
| Middle Aged | 93 | 2020 | 11824 | 1.540 |
Why?
|
| Age Factors | 43 | 2020 | 1187 | 1.520 |
Why?
|
| Vitamin K 1 | 6 | 2020 | 11 | 1.490 |
Why?
|
| United States | 73 | 2020 | 3925 | 1.470 |
Why?
|
| Genetic Loci | 14 | 2019 | 146 | 1.450 |
Why?
|
| C-Reactive Protein | 30 | 2018 | 239 | 1.450 |
Why?
|
| Cognition | 17 | 2020 | 551 | 1.430 |
Why?
|
| Exercise Therapy | 12 | 2019 | 268 | 1.420 |
Why?
|
| Hospitalization | 15 | 2018 | 463 | 1.370 |
Why?
|
| Deglutition Disorders | 7 | 2017 | 50 | 1.360 |
Why?
|
| Incidence | 45 | 2020 | 1192 | 1.310 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 297 | 1.290 |
Why?
|
| Proportional Hazards Models | 38 | 2020 | 756 | 1.220 |
Why?
|
| Resistance Training | 5 | 2018 | 79 | 1.160 |
Why?
|
| African Americans | 31 | 2020 | 1428 | 1.150 |
Why?
|
| Tennessee | 36 | 2020 | 100 | 1.140 |
Why?
|
| Smoking | 22 | 2020 | 499 | 1.120 |
Why?
|
| Continental Population Groups | 14 | 2020 | 236 | 1.120 |
Why?
|
| Diet, Reducing | 4 | 2017 | 102 | 1.100 |
Why?
|
| Body Weight | 24 | 2020 | 306 | 1.080 |
Why?
|
| Health Education | 16 | 2020 | 157 | 1.060 |
Why?
|
| African Continental Ancestry Group | 25 | 2019 | 363 | 1.060 |
Why?
|
| Parathyroid Hormone | 8 | 2020 | 41 | 1.030 |
Why?
|
| Sodium, Dietary | 2 | 2015 | 23 | 1.020 |
Why?
|
| Dietary Supplements | 10 | 2020 | 185 | 1.010 |
Why?
|
| Cross-Sectional Studies | 51 | 2020 | 1527 | 1.010 |
Why?
|
| Overweight | 13 | 2020 | 276 | 0.990 |
Why?
|
| Sex Factors | 34 | 2020 | 662 | 0.970 |
Why?
|
| Pennsylvania | 33 | 2020 | 83 | 0.960 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2020 | 504 | 0.950 |
Why?
|
| Hypoglycemic Agents | 5 | 2020 | 181 | 0.940 |
Why?
|
| Energy Metabolism | 7 | 2020 | 148 | 0.940 |
Why?
|
| DNA Methylation | 4 | 2020 | 140 | 0.930 |
Why?
|
| Renal Insufficiency, Chronic | 10 | 2020 | 288 | 0.920 |
Why?
|
| Tumor Necrosis Factor-alpha | 21 | 2013 | 211 | 0.910 |
Why?
|
| Laryngoscopy | 3 | 2017 | 40 | 0.910 |
Why?
|
| Hypertension | 17 | 2020 | 956 | 0.890 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 9 | 2019 | 151 | 0.880 |
Why?
|
| Lipoproteins, LDL | 6 | 2012 | 81 | 0.870 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2020 | 1424 | 0.840 |
Why?
|
| Cross Infection | 5 | 2011 | 49 | 0.840 |
Why?
|
| Accidental Falls | 7 | 2016 | 221 | 0.830 |
Why?
|
| Diet | 12 | 2020 | 385 | 0.820 |
Why?
|
| Pneumonia | 5 | 2013 | 66 | 0.820 |
Why?
|
| Cognition Disorders | 11 | 2018 | 384 | 0.810 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2020 | 200 | 0.800 |
Why?
|
| Tongue | 2 | 2012 | 13 | 0.800 |
Why?
|
| Thiazolidinediones | 2 | 2013 | 47 | 0.800 |
Why?
|
| Dietary Proteins | 8 | 2020 | 52 | 0.790 |
Why?
|
| Physical Examination | 3 | 2019 | 92 | 0.780 |
Why?
|
| Independent Living | 12 | 2020 | 99 | 0.780 |
Why?
|
| Genetic Markers | 4 | 2020 | 124 | 0.770 |
Why?
|
| Blood Glucose | 13 | 2016 | 491 | 0.750 |
Why?
|
| Urinary Incontinence | 2 | 2018 | 47 | 0.730 |
Why?
|
| Surgical Wound Infection | 3 | 2010 | 85 | 0.720 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2020 | 135 | 0.710 |
Why?
|
| Nutrition Assessment | 4 | 2018 | 55 | 0.690 |
Why?
|
| Nutritional Status | 3 | 2016 | 75 | 0.690 |
Why?
|
| Diabetes Mellitus | 10 | 2020 | 409 | 0.680 |
Why?
|
| Physical Endurance | 6 | 2015 | 35 | 0.660 |
Why?
|
| Absorptiometry, Photon | 24 | 2019 | 137 | 0.660 |
Why?
|
| Atherosclerosis | 9 | 2020 | 767 | 0.660 |
Why?
|
| DNA, Mitochondrial | 5 | 2018 | 34 | 0.650 |
Why?
|
| Periodicals as Topic | 2 | 2018 | 91 | 0.640 |
Why?
|
| Biomedical Research | 4 | 2020 | 155 | 0.640 |
Why?
|
| Risk Assessment | 23 | 2020 | 1431 | 0.640 |
Why?
|
| Gait Disorders, Neurologic | 5 | 2017 | 14 | 0.640 |
Why?
|
| Ethnic Groups | 6 | 2017 | 476 | 0.630 |
Why?
|
| Geriatric Nursing | 1 | 2018 | 2 | 0.620 |
Why?
|
| Lipids | 5 | 2019 | 228 | 0.620 |
Why?
|
| Peer Review, Research | 1 | 2018 | 9 | 0.620 |
Why?
|
| Health Promotion | 5 | 2012 | 246 | 0.610 |
Why?
|
| Leg | 6 | 2013 | 66 | 0.610 |
Why?
|
| Fibroblast Growth Factors | 6 | 2020 | 35 | 0.610 |
Why?
|
| Muscle Weakness | 6 | 2016 | 37 | 0.610 |
Why?
|
| Respiratory Function Tests | 9 | 2019 | 108 | 0.610 |
Why?
|
| Single-Blind Method | 15 | 2020 | 201 | 0.600 |
Why?
|
| Prognosis | 26 | 2019 | 1498 | 0.600 |
Why?
|
| Genotype | 21 | 2019 | 727 | 0.590 |
Why?
|
| Coronary Vessels | 3 | 2013 | 158 | 0.590 |
Why?
|
| Pilot Projects | 18 | 2020 | 537 | 0.590 |
Why?
|
| Alzheimer Disease | 3 | 2018 | 327 | 0.590 |
Why?
|
| Community-Acquired Infections | 4 | 2013 | 30 | 0.580 |
Why?
|
| Comorbidity | 18 | 2020 | 566 | 0.580 |
Why?
|
| Reference Values | 11 | 2017 | 247 | 0.580 |
Why?
|
| Nutritional Requirements | 2 | 2016 | 16 | 0.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2016 | 144 | 0.580 |
Why?
|
| Critical Illness | 1 | 2018 | 87 | 0.570 |
Why?
|
| Hearing Loss | 4 | 2020 | 26 | 0.560 |
Why?
|
| Social Class | 5 | 2014 | 88 | 0.550 |
Why?
|
| Thinness | 5 | 2017 | 32 | 0.550 |
Why?
|
| Neoplasms | 7 | 2020 | 692 | 0.550 |
Why?
|
| Quality Indicators, Health Care | 4 | 2011 | 59 | 0.550 |
Why?
|
| Longevity | 3 | 2020 | 24 | 0.540 |
Why?
|
| Lung Diseases | 5 | 2018 | 47 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2019 | 912 | 0.530 |
Why?
|
| Adult | 38 | 2020 | 9327 | 0.530 |
Why?
|
| Muscular Atrophy | 9 | 2012 | 70 | 0.530 |
Why?
|
| Intra-Abdominal Fat | 4 | 2012 | 63 | 0.530 |
Why?
|
| Blood Pressure | 10 | 2020 | 843 | 0.530 |
Why?
|
| Polymorphism, Genetic | 5 | 2010 | 184 | 0.520 |
Why?
|
| Research | 2 | 2018 | 74 | 0.520 |
Why?
|
| Bone Density | 4 | 2020 | 194 | 0.520 |
Why?
|
| Alcohol Drinking | 8 | 2018 | 247 | 0.510 |
Why?
|
| Odds Ratio | 9 | 2017 | 470 | 0.510 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2020 | 56 | 0.500 |
Why?
|
| Severity of Illness Index | 13 | 2019 | 899 | 0.500 |
Why?
|
| Cytokines | 6 | 2012 | 259 | 0.500 |
Why?
|
| Linear Models | 23 | 2018 | 449 | 0.490 |
Why?
|
| Cholesterol, LDL | 6 | 2019 | 173 | 0.490 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 470 | 0.490 |
Why?
|
| Calcium | 3 | 2013 | 304 | 0.490 |
Why?
|
| Time Factors | 19 | 2018 | 2146 | 0.480 |
Why?
|
| Lung | 6 | 2018 | 255 | 0.470 |
Why?
|
| Patient Compliance | 4 | 2019 | 224 | 0.470 |
Why?
|
| Cooperative Behavior | 3 | 2016 | 81 | 0.470 |
Why?
|
| Aorta | 3 | 2011 | 125 | 0.470 |
Why?
|
| Exercise Test | 11 | 2016 | 225 | 0.470 |
Why?
|
| Logistic Models | 19 | 2016 | 777 | 0.460 |
Why?
|
| Brain | 8 | 2015 | 949 | 0.460 |
Why?
|
| Mitochondria | 1 | 2015 | 186 | 0.460 |
Why?
|
| Multivariate Analysis | 17 | 2018 | 686 | 0.440 |
Why?
|
| Phenotype | 13 | 2019 | 635 | 0.440 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 8 | 2012 | 44 | 0.440 |
Why?
|
| Case-Control Studies | 14 | 2020 | 895 | 0.440 |
Why?
|
| Cause of Death | 8 | 2016 | 238 | 0.430 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2018 | 835 | 0.430 |
Why?
|
| Vital Capacity | 7 | 2018 | 44 | 0.420 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 8 | 0.420 |
Why?
|
| Macula Lutea | 3 | 2014 | 9 | 0.420 |
Why?
|
| Levodopa | 1 | 2012 | 14 | 0.420 |
Why?
|
| Reflex | 1 | 2012 | 15 | 0.420 |
Why?
|
| Adiponectin | 6 | 2013 | 106 | 0.420 |
Why?
|
| Laryngeal Muscles | 1 | 2012 | 16 | 0.420 |
Why?
|
| Dopamine Agents | 1 | 2012 | 19 | 0.420 |
Why?
|
| Lower Extremity | 4 | 2018 | 100 | 0.420 |
Why?
|
| Predictive Value of Tests | 18 | 2019 | 874 | 0.410 |
Why?
|
| Forced Expiratory Volume | 10 | 2018 | 97 | 0.410 |
Why?
|
| Gastrointestinal Transit | 1 | 2011 | 4 | 0.400 |
Why?
|
| Genetic Variation | 6 | 2016 | 245 | 0.400 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2009 | 37 | 0.400 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2012 | 26 | 0.400 |
Why?
|
| Locomotion | 4 | 2005 | 31 | 0.400 |
Why?
|
| Housing, Animal | 1 | 2011 | 23 | 0.400 |
Why?
|
| Catheterization, Central Venous | 3 | 2008 | 62 | 0.400 |
Why?
|
| Vitamin K | 3 | 2018 | 9 | 0.390 |
Why?
|
| Caloric Restriction | 4 | 2020 | 95 | 0.390 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2011 | 25 | 0.390 |
Why?
|
| Risk | 15 | 2020 | 318 | 0.380 |
Why?
|
| Intensive Care Units | 4 | 2008 | 109 | 0.380 |
Why?
|
| Losartan | 3 | 2019 | 64 | 0.380 |
Why?
|
| Coronary Disease | 4 | 2011 | 213 | 0.380 |
Why?
|
| Animals | 18 | 2020 | 7450 | 0.370 |
Why?
|
| Health Behavior | 5 | 2019 | 231 | 0.370 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2010 | 132 | 0.370 |
Why?
|
| Esophageal Sphincter, Upper | 1 | 2010 | 3 | 0.370 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 48 | 0.370 |
Why?
|
| Prevalence | 18 | 2020 | 979 | 0.370 |
Why?
|
| Pharynx | 1 | 2010 | 13 | 0.370 |
Why?
|
| Retinal Pigments | 2 | 2007 | 7 | 0.370 |
Why?
|
| Oxidative Stress | 4 | 2015 | 229 | 0.360 |
Why?
|
| Cholesterol, Dietary | 3 | 2012 | 36 | 0.360 |
Why?
|
| Forms and Records Control | 1 | 2010 | 7 | 0.360 |
Why?
|
| Mandatory Reporting | 1 | 2010 | 7 | 0.360 |
Why?
|
| Metformin | 3 | 2020 | 22 | 0.360 |
Why?
|
| Tumor Necrosis Factors | 2 | 2010 | 5 | 0.360 |
Why?
|
| Coronary Artery Disease | 5 | 2016 | 398 | 0.350 |
Why?
|
| Chronic Disease | 8 | 2017 | 400 | 0.350 |
Why?
|
| Medical Records | 1 | 2010 | 76 | 0.350 |
Why?
|
| Sex Distribution | 11 | 2015 | 195 | 0.350 |
Why?
|
| Fractures, Bone | 3 | 2020 | 144 | 0.340 |
Why?
|
| Cholesterol | 6 | 2019 | 251 | 0.340 |
Why?
|
| Appetite | 3 | 2017 | 22 | 0.340 |
Why?
|
| Health Surveys | 12 | 2014 | 196 | 0.340 |
Why?
|
| Dogs | 2 | 2006 | 116 | 0.340 |
Why?
|
| Heart Failure, Diastolic | 1 | 2009 | 15 | 0.330 |
Why?
|
| Osteoarthritis, Knee | 4 | 2018 | 90 | 0.330 |
Why?
|
| Insulin | 6 | 2016 | 366 | 0.320 |
Why?
|
| Glucuronidase | 3 | 2020 | 12 | 0.320 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2014 | 51 | 0.320 |
Why?
|
| Hospitals | 2 | 2008 | 98 | 0.320 |
Why?
|
| Myocardial Infarction | 8 | 2017 | 480 | 0.310 |
Why?
|
| Young Adult | 11 | 2019 | 2603 | 0.310 |
Why?
|
| Dementia | 3 | 2020 | 251 | 0.310 |
Why?
|
| Adipokines | 1 | 2008 | 16 | 0.310 |
Why?
|
| Exercise Tolerance | 5 | 2013 | 124 | 0.310 |
Why?
|
| Photometry | 2 | 2007 | 3 | 0.310 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 109 | 0.310 |
Why?
|
| Health | 4 | 2020 | 14 | 0.300 |
Why?
|
| Models, Statistical | 4 | 2015 | 173 | 0.290 |
Why?
|
| Bacteremia | 1 | 2008 | 58 | 0.290 |
Why?
|
| Treatment Outcome | 9 | 2019 | 3294 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 7 | 2018 | 305 | 0.290 |
Why?
|
| Dyspnea | 2 | 2019 | 32 | 0.290 |
Why?
|
| Calcinosis | 4 | 2017 | 145 | 0.280 |
Why?
|
| Eating | 2 | 2017 | 74 | 0.280 |
Why?
|
| Sertraline | 2 | 2017 | 27 | 0.280 |
Why?
|
| Women's Health | 4 | 2016 | 235 | 0.280 |
Why?
|
| Animals, Domestic | 1 | 2006 | 3 | 0.270 |
Why?
|
| Kidney | 5 | 2018 | 515 | 0.270 |
Why?
|
| Abdominal Fat | 3 | 2012 | 49 | 0.270 |
Why?
|
| Neuropsychological Tests | 9 | 2017 | 370 | 0.270 |
Why?
|
| Anthropometry | 6 | 2017 | 83 | 0.270 |
Why?
|
| Pericardium | 3 | 2013 | 52 | 0.270 |
Why?
|
| Feeding Behavior | 3 | 2019 | 161 | 0.260 |
Why?
|
| Chi-Square Distribution | 10 | 2012 | 298 | 0.260 |
Why?
|
| Body Fat Distribution | 4 | 2017 | 34 | 0.260 |
Why?
|
| Knee | 3 | 2015 | 33 | 0.260 |
Why?
|
| Smell | 2 | 2016 | 48 | 0.260 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 764 | 0.260 |
Why?
|
| Quadriceps Muscle | 2 | 2016 | 34 | 0.260 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2015 | 83 | 0.260 |
Why?
|
| Waist Circumference | 5 | 2017 | 90 | 0.250 |
Why?
|
| Genome, Human | 6 | 2018 | 132 | 0.250 |
Why?
|
| Lutein | 3 | 2014 | 4 | 0.250 |
Why?
|
| Extracellular Matrix Proteins | 5 | 2020 | 45 | 0.250 |
Why?
|
| Body Constitution | 3 | 2017 | 25 | 0.250 |
Why?
|
| Eggs | 1 | 2004 | 4 | 0.250 |
Why?
|
| Research Design | 5 | 2020 | 310 | 0.250 |
Why?
|
| Hippocampus | 2 | 2017 | 171 | 0.250 |
Why?
|
| Inflammation Mediators | 5 | 2012 | 105 | 0.250 |
Why?
|
| Muscle Contraction | 4 | 2017 | 113 | 0.250 |
Why?
|
| Survival Rate | 9 | 2020 | 884 | 0.250 |
Why?
|
| Ambulatory Care Facilities | 1 | 2005 | 83 | 0.240 |
Why?
|
| Nutrition Policy | 1 | 2004 | 35 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 540 | 0.240 |
Why?
|
| Retrospective Studies | 13 | 2019 | 3488 | 0.240 |
Why?
|
| Poverty | 1 | 2005 | 111 | 0.240 |
Why?
|
| Diet Surveys | 4 | 2019 | 57 | 0.240 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2016 | 5 | 0.230 |
Why?
|
| Antidepressive Agents | 4 | 2017 | 74 | 0.230 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 515 | 0.230 |
Why?
|
| Disease Progression | 6 | 2017 | 593 | 0.230 |
Why?
|
| Peripheral Nerves | 2 | 2014 | 62 | 0.230 |
Why?
|
| Double-Blind Method | 6 | 2019 | 523 | 0.230 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 104 | 0.230 |
Why?
|
| Energy Intake | 6 | 2019 | 126 | 0.230 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2016 | 109 | 0.230 |
Why?
|
| Referral and Consultation | 1 | 2005 | 140 | 0.230 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 31 | 0.230 |
Why?
|
| Health Status Indicators | 4 | 2020 | 73 | 0.230 |
Why?
|
| Monocytes | 2 | 2015 | 126 | 0.230 |
Why?
|
| Macular Degeneration | 2 | 2015 | 22 | 0.220 |
Why?
|
| Aspirin | 1 | 2003 | 64 | 0.220 |
Why?
|
| Lipid Peroxidation | 4 | 2013 | 32 | 0.220 |
Why?
|
| Resistin | 2 | 2015 | 4 | 0.220 |
Why?
|
| Calcium-Binding Proteins | 4 | 2020 | 45 | 0.220 |
Why?
|
| Bone and Bones | 1 | 2003 | 91 | 0.220 |
Why?
|
| Membrane Glycoproteins | 2 | 2014 | 102 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 73 | 0.220 |
Why?
|
| Quality of Life | 5 | 2019 | 924 | 0.220 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2013 | 5 | 0.210 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 125 | 0.210 |
Why?
|
| Survival Analysis | 10 | 2020 | 487 | 0.210 |
Why?
|
| Heart Diseases | 2 | 2018 | 115 | 0.210 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2015 | 7 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2016 | 155 | 0.210 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2015 | 20 | 0.210 |
Why?
|
| Postmenopause | 5 | 2016 | 413 | 0.200 |
Why?
|
| Restraint, Physical | 1 | 2002 | 10 | 0.200 |
Why?
|
| Triglycerides | 4 | 2019 | 230 | 0.200 |
Why?
|
| Gene Expression Regulation | 5 | 2017 | 493 | 0.200 |
Why?
|
| Adolescent | 11 | 2019 | 3511 | 0.200 |
Why?
|
| Thigh | 5 | 2018 | 41 | 0.200 |
Why?
|
| Regression Analysis | 8 | 2018 | 293 | 0.200 |
Why?
|
| Viscosity | 2 | 2011 | 22 | 0.200 |
Why?
|
| Hyperglycemia | 2 | 2016 | 84 | 0.200 |
Why?
|
| Laryngoscopes | 2 | 2011 | 12 | 0.190 |
Why?
|
| Sensory Thresholds | 3 | 2015 | 28 | 0.190 |
Why?
|
| Postural Balance | 4 | 2017 | 182 | 0.190 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2017 | 29 | 0.190 |
Why?
|
| Fasting | 5 | 2016 | 95 | 0.190 |
Why?
|
| Cholesterol, HDL | 5 | 2019 | 177 | 0.190 |
Why?
|
| Quantitative Trait Loci | 6 | 2018 | 140 | 0.190 |
Why?
|
| Antioxidants | 4 | 2013 | 114 | 0.190 |
Why?
|
| Bone Remodeling | 1 | 2020 | 9 | 0.190 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 15 | 0.180 |
Why?
|
| Antihypertensive Agents | 5 | 2020 | 351 | 0.180 |
Why?
|
| Diabetes Complications | 4 | 2018 | 177 | 0.180 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2018 | 15 | 0.180 |
Why?
|
| Socioeconomic Factors | 5 | 2018 | 420 | 0.180 |
Why?
|
| Leisure Activities | 1 | 2020 | 13 | 0.180 |
Why?
|
| Sex Characteristics | 6 | 2012 | 169 | 0.180 |
Why?
|
| Dietary Carbohydrates | 2 | 2013 | 22 | 0.180 |
Why?
|
| Vitamins | 3 | 2015 | 68 | 0.180 |
Why?
|
| Magnesium | 2 | 2013 | 30 | 0.170 |
Why?
|
| Phylogeny | 1 | 2019 | 54 | 0.170 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 11 | 0.170 |
Why?
|
| Asian Continental Ancestry Group | 3 | 2019 | 108 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 3 | 2011 | 103 | 0.170 |
Why?
|
| Heart Rate | 4 | 2017 | 332 | 0.170 |
Why?
|
| Platelet Activation | 2 | 2012 | 13 | 0.170 |
Why?
|
| Memory Disorders | 1 | 2020 | 54 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 22 | 0.170 |
Why?
|
| Confidence Intervals | 8 | 2015 | 148 | 0.170 |
Why?
|
| Fatigue | 1 | 2019 | 84 | 0.170 |
Why?
|
| Hyperlipidemias | 2 | 2014 | 54 | 0.170 |
Why?
|
| Posture | 2 | 2017 | 54 | 0.170 |
Why?
|
| Cough | 1 | 2019 | 19 | 0.170 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 65 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 29 | 0.170 |
Why?
|
| Psoas Muscles | 1 | 2019 | 19 | 0.170 |
Why?
|
| Body Fluid Compartments | 1 | 2019 | 5 | 0.170 |
Why?
|
| Organ Size | 6 | 2019 | 208 | 0.170 |
Why?
|
| Quercetin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 7 | 0.170 |
Why?
|
| Epistasis, Genetic | 2 | 2018 | 44 | 0.170 |
Why?
|
| Specialization | 1 | 2019 | 31 | 0.170 |
Why?
|
| Respiratory Muscles | 1 | 2018 | 6 | 0.160 |
Why?
|
| Mentors | 1 | 2019 | 31 | 0.160 |
Why?
|
| Haplotypes | 3 | 2011 | 220 | 0.160 |
Why?
|
| Analysis of Variance | 8 | 2017 | 461 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2017 | 1323 | 0.160 |
Why?
|
| Algorithms | 3 | 2019 | 495 | 0.160 |
Why?
|
| Sleep | 1 | 2019 | 92 | 0.160 |
Why?
|
| Leadership | 1 | 2019 | 37 | 0.160 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 19 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 99 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 103 | 0.160 |
Why?
|
| Peroneal Nerve | 2 | 2015 | 15 | 0.160 |
Why?
|
| Weight Gain | 6 | 2010 | 116 | 0.160 |
Why?
|
| Random Allocation | 5 | 2019 | 218 | 0.160 |
Why?
|
| Autophagy | 2 | 2015 | 52 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 20 | 0.160 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2018 | 4 | 0.160 |
Why?
|
| Creatinine | 7 | 2015 | 195 | 0.160 |
Why?
|
| Calcitriol | 1 | 2018 | 25 | 0.160 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 10 | 0.150 |
Why?
|
| Seafood | 1 | 2017 | 11 | 0.150 |
Why?
|
| Receptors, Cytokine | 2 | 2016 | 8 | 0.150 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 21 | 0.150 |
Why?
|
| Serum Albumin | 2 | 2010 | 54 | 0.150 |
Why?
|
| Diffusion Tensor Imaging | 5 | 2015 | 28 | 0.150 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2013 | 14 | 0.150 |
Why?
|
| Sensitivity and Specificity | 7 | 2014 | 589 | 0.150 |
Why?
|
| Insurance, Health | 2 | 2012 | 95 | 0.150 |
Why?
|
| Motor Neurons | 2 | 2015 | 56 | 0.150 |
Why?
|
| Neural Pathways | 2 | 2017 | 94 | 0.150 |
Why?
|
| Neural Conduction | 2 | 2015 | 91 | 0.150 |
Why?
|
| Glycemic Index | 2 | 2009 | 14 | 0.150 |
Why?
|
| Morbidity | 2 | 2016 | 99 | 0.150 |
Why?
|
| Primary Prevention | 1 | 2017 | 54 | 0.150 |
Why?
|
| Avitaminosis | 1 | 2017 | 2 | 0.150 |
Why?
|
| Metabolomics | 1 | 2017 | 52 | 0.150 |
Why?
|
| Heart | 1 | 2018 | 178 | 0.150 |
Why?
|
| Muscle Denervation | 1 | 2017 | 28 | 0.150 |
Why?
|
| Publishing | 1 | 2018 | 60 | 0.150 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2017 | 29 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2014 | 24 | 0.140 |
Why?
|
| Carbohydrate Metabolism | 2 | 2016 | 15 | 0.140 |
Why?
|
| Medicine | 1 | 2017 | 38 | 0.140 |
Why?
|
| Amino Acids | 1 | 2017 | 46 | 0.140 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 71 | 0.140 |
Why?
|
| Models, Anatomic | 1 | 2017 | 39 | 0.140 |
Why?
|
| Alleles | 6 | 2016 | 248 | 0.140 |
Why?
|
| Forecasting | 2 | 2015 | 144 | 0.140 |
Why?
|
| Kidney Function Tests | 5 | 2018 | 106 | 0.140 |
Why?
|
| Oxygen Consumption | 2 | 2014 | 152 | 0.140 |
Why?
|
| Stroke | 6 | 2017 | 581 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2019 | 257 | 0.140 |
Why?
|
| Proteins | 2 | 2020 | 144 | 0.140 |
Why?
|
| Age Distribution | 7 | 2015 | 206 | 0.140 |
Why?
|
| Gene Expression | 2 | 2014 | 334 | 0.140 |
Why?
|
| Probability | 4 | 2009 | 158 | 0.130 |
Why?
|
| Troponin T | 1 | 2017 | 80 | 0.130 |
Why?
|
| Homes for the Aged | 1 | 2016 | 20 | 0.130 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 55 | 0.130 |
Why?
|
| Autoantigens | 1 | 2015 | 16 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2018 | 325 | 0.130 |
Why?
|
| Xanthophylls | 2 | 2014 | 3 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 46 | 0.130 |
Why?
|
| Gene Frequency | 5 | 2018 | 220 | 0.130 |
Why?
|
| Erythropoietin | 1 | 2016 | 30 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2015 | 32 | 0.130 |
Why?
|
| Pressure | 2 | 2018 | 51 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2013 | 8 | 0.130 |
Why?
|
| Hispanic Americans | 4 | 2019 | 942 | 0.130 |
Why?
|
| Extremities | 1 | 2016 | 51 | 0.130 |
Why?
|
| Mitochondrial Diseases | 1 | 2015 | 11 | 0.130 |
Why?
|
| Sensation Disorders | 1 | 2015 | 20 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2015 | 49 | 0.130 |
Why?
|
| Homebound Persons | 1 | 2015 | 9 | 0.130 |
Why?
|
| Cholecalciferol | 1 | 2015 | 20 | 0.130 |
Why?
|
| Mental Health | 1 | 2016 | 115 | 0.130 |
Why?
|
| Models, Biological | 3 | 2016 | 391 | 0.130 |
Why?
|
| Hip Fractures | 2 | 2012 | 30 | 0.130 |
Why?
|
| Food Services | 1 | 2015 | 20 | 0.130 |
Why?
|
| Publication Bias | 1 | 2015 | 8 | 0.130 |
Why?
|
| Memory | 2 | 2014 | 190 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2016 | 183 | 0.130 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 18 | 0.130 |
Why?
|
| Periodontal Diseases | 2 | 2005 | 16 | 0.120 |
Why?
|
| Toes | 1 | 2014 | 15 | 0.120 |
Why?
|
| Accidents, Occupational | 1 | 2015 | 16 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 159 | 0.120 |
Why?
|
| Joint Diseases | 1 | 2015 | 37 | 0.120 |
Why?
|
| Leptin | 3 | 2013 | 71 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2017 | 180 | 0.120 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2014 | 9 | 0.120 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2014 | 2 | 0.120 |
Why?
|
| Motor Skills Disorders | 1 | 2014 | 7 | 0.120 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 23 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 57 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2014 | 11 | 0.120 |
Why?
|
| Mitochondria, Muscle | 1 | 2014 | 18 | 0.120 |
Why?
|
| Respiration | 1 | 2014 | 27 | 0.120 |
Why?
|
| Depressive Disorder | 4 | 2013 | 75 | 0.120 |
Why?
|
| Interleukin-18 | 1 | 2014 | 9 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 56 | 0.120 |
Why?
|
| Kidney Diseases | 2 | 2007 | 249 | 0.120 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2015 | 85 | 0.120 |
Why?
|
| Body Height | 2 | 2011 | 35 | 0.120 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2013 | 11 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2014 | 102 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 760 | 0.120 |
Why?
|
| Phosphorus | 2 | 2011 | 10 | 0.120 |
Why?
|
| Hyoid Bone | 1 | 2013 | 5 | 0.120 |
Why?
|
| Reaction Time | 2 | 2012 | 117 | 0.120 |
Why?
|
| Apoptosis | 1 | 2015 | 354 | 0.110 |
Why?
|
| Mammography | 1 | 2013 | 42 | 0.110 |
Why?
|
| Water | 2 | 2010 | 56 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2014 | 65 | 0.110 |
Why?
|
| Oral Hygiene | 1 | 2013 | 16 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 57 | 0.110 |
Why?
|
| Catheters, Indwelling | 2 | 2003 | 42 | 0.110 |
Why?
|
| Breast | 1 | 2013 | 61 | 0.110 |
Why?
|
| Sepsis | 2 | 2006 | 158 | 0.110 |
Why?
|
| Trace Elements | 1 | 2013 | 7 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 132 | 0.110 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 9 | 0.110 |
Why?
|
| Pharyngeal Muscles | 1 | 2012 | 5 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2010 | 48 | 0.110 |
Why?
|
| Feasibility Studies | 4 | 2019 | 291 | 0.110 |
Why?
|
| Models, Animal | 3 | 2020 | 164 | 0.110 |
Why?
|
| Bacterial Translocation | 1 | 2012 | 8 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 10 | 0.110 |
Why?
|
| Laryngeal Nerves | 1 | 2012 | 4 | 0.110 |
Why?
|
| Blood Flow Velocity | 2 | 2011 | 76 | 0.110 |
Why?
|
| Dietary Fats | 1 | 2013 | 110 | 0.110 |
Why?
|
| Psychomotor Performance | 3 | 2011 | 99 | 0.110 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2012 | 15 | 0.100 |
Why?
|
| Population Dynamics | 1 | 2012 | 6 | 0.100 |
Why?
|
| Developed Countries | 2 | 2012 | 4 | 0.100 |
Why?
|
| Hypokinesia | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cystatins | 3 | 2007 | 8 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 7 | 0.100 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 133 | 0.100 |
Why?
|
| Homeostasis | 1 | 2012 | 132 | 0.100 |
Why?
|
| Cercopithecidae | 1 | 2011 | 10 | 0.100 |
Why?
|
| Psychology | 1 | 2012 | 24 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 322 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 16 | 0.100 |
Why?
|
| Europe | 4 | 2017 | 83 | 0.100 |
Why?
|
| Esophageal Motility Disorders | 1 | 2011 | 6 | 0.100 |
Why?
|
| Stroke Volume | 5 | 2013 | 341 | 0.100 |
Why?
|
| Ankle Brachial Index | 1 | 2011 | 38 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 3 | 2018 | 23 | 0.100 |
Why?
|
| Food | 1 | 2011 | 43 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2012 | 137 | 0.100 |
Why?
|
| Health Policy | 1 | 2012 | 82 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 24 | 0.100 |
Why?
|
| Medicare | 3 | 2019 | 206 | 0.100 |
Why?
|
| Statistics as Topic | 4 | 2017 | 107 | 0.100 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2011 | 5 | 0.100 |
Why?
|
| Intention | 1 | 2011 | 28 | 0.100 |
Why?
|
| Neurologic Examination | 3 | 2016 | 28 | 0.100 |
Why?
|
| Minerals | 1 | 2011 | 14 | 0.100 |
Why?
|
| Zinc | 1 | 2011 | 32 | 0.100 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2011 | 3 | 0.100 |
Why?
|
| Epidemiology | 1 | 2011 | 6 | 0.100 |
Why?
|
| Manometry | 1 | 2011 | 19 | 0.100 |
Why?
|
| Private Sector | 1 | 2011 | 8 | 0.100 |
Why?
|
| Systole | 3 | 2020 | 99 | 0.090 |
Why?
|
| Choristoma | 1 | 2011 | 16 | 0.090 |
Why?
|
| Societies, Scientific | 1 | 2011 | 15 | 0.090 |
Why?
|
| Mice | 4 | 2020 | 2476 | 0.090 |
Why?
|
| Interleukins | 1 | 2010 | 19 | 0.090 |
Why?
|
| Anisotropy | 3 | 2015 | 11 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2011 | 46 | 0.090 |
Why?
|
| Rats | 2 | 2012 | 1586 | 0.090 |
Why?
|
| F2-Isoprostanes | 1 | 2010 | 20 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2016 | 779 | 0.090 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 47 | 0.090 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2007 | 8 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2015 | 53 | 0.090 |
Why?
|
| Milk | 1 | 2010 | 16 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2012 | 251 | 0.090 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2014 | 28 | 0.090 |
Why?
|
| Equipment Design | 1 | 2010 | 172 | 0.090 |
Why?
|
| Ideal Body Weight | 1 | 2009 | 7 | 0.090 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 2014 | 16 | 0.090 |
Why?
|
| Weight Lifting | 2 | 2006 | 10 | 0.090 |
Why?
|
| Bicycling | 1 | 2009 | 14 | 0.090 |
Why?
|
| Cardiac Output | 1 | 2009 | 36 | 0.090 |
Why?
|
| Affect | 1 | 2010 | 69 | 0.090 |
Why?
|
| Urban Population | 2 | 2012 | 89 | 0.090 |
Why?
|
| Estrogens | 2 | 2014 | 167 | 0.080 |
Why?
|
| Fosinopril | 1 | 2009 | 2 | 0.080 |
Why?
|
| Fibrinolysis | 1 | 2009 | 7 | 0.080 |
Why?
|
| Waiting Lists | 1 | 2009 | 34 | 0.080 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 24 | 0.080 |
Why?
|
| Muscle Cells | 1 | 2009 | 7 | 0.080 |
Why?
|
| Waist-Hip Ratio | 3 | 2016 | 34 | 0.080 |
Why?
|
| Diastole | 2 | 2020 | 96 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2010 | 147 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2012 | 461 | 0.080 |
Why?
|
| Child | 5 | 2018 | 2425 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 178 | 0.080 |
Why?
|
| North Carolina | 4 | 2019 | 1514 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 2008 | 22 | 0.080 |
Why?
|
| Coronary Stenosis | 1 | 2008 | 30 | 0.080 |
Why?
|
| Feedback | 1 | 2008 | 43 | 0.080 |
Why?
|
| Versicans | 2 | 2019 | 4 | 0.080 |
Why?
|
| Cystatin C | 4 | 2012 | 31 | 0.080 |
Why?
|
| Blood-Borne Pathogens | 1 | 2008 | 7 | 0.080 |
Why?
|
| Viscera | 2 | 2004 | 17 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 2008 | 11 | 0.080 |
Why?
|
| Seasons | 3 | 2015 | 87 | 0.080 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 28 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 55 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2007 | 27 | 0.070 |
Why?
|
| Pseudophakia | 1 | 2007 | 3 | 0.070 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 7 | 0.070 |
Why?
|
| Infection Control | 2 | 2003 | 28 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 245 | 0.070 |
Why?
|
| Fear | 1 | 2007 | 48 | 0.070 |
Why?
|
| Nutrition Surveys | 2 | 2005 | 147 | 0.070 |
Why?
|
| Ownership | 1 | 2006 | 15 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 88 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 3 | 2012 | 76 | 0.070 |
Why?
|
| Educational Status | 3 | 2014 | 178 | 0.070 |
Why?
|
| Peroxidase | 1 | 2006 | 31 | 0.070 |
Why?
|
| Menopause | 1 | 2007 | 92 | 0.070 |
Why?
|
| Stem Cells | 1 | 2009 | 312 | 0.070 |
Why?
|
| Hypercholesterolemia | 2 | 2004 | 69 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2007 | 113 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2007 | 121 | 0.070 |
Why?
|
| Periodontitis | 1 | 2005 | 9 | 0.070 |
Why?
|
| Audiometry, Pure-Tone | 2 | 2016 | 8 | 0.070 |
Why?
|
| Airway Obstruction | 1 | 2005 | 30 | 0.070 |
Why?
|
| Chromosome Mapping | 2 | 2019 | 193 | 0.060 |
Why?
|
| Pulse | 1 | 2005 | 10 | 0.060 |
Why?
|
| Food Preferences | 1 | 2005 | 36 | 0.060 |
Why?
|
| Health Services for the Aged | 2 | 2018 | 24 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2019 | 120 | 0.060 |
Why?
|
| Acceleration | 1 | 2005 | 65 | 0.060 |
Why?
|
| Anxiety | 1 | 2007 | 188 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2005 | 31 | 0.060 |
Why?
|
| Patient Selection | 1 | 2007 | 276 | 0.060 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 43 | 0.060 |
Why?
|
| Vibration | 2 | 2015 | 11 | 0.060 |
Why?
|
| Knee Joint | 3 | 2017 | 142 | 0.060 |
Why?
|
| Muscle Fatigue | 1 | 2005 | 12 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 1012 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2019 | 186 | 0.060 |
Why?
|
| Atrophy | 2 | 2017 | 46 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2005 | 30 | 0.060 |
Why?
|
| Alendronate | 1 | 2004 | 10 | 0.060 |
Why?
|
| Bone Resorption | 1 | 2004 | 12 | 0.060 |
Why?
|
| Preventive Health Services | 1 | 2005 | 44 | 0.060 |
Why?
|
| beta Carotene | 1 | 2004 | 6 | 0.060 |
Why?
|
| Muscles | 2 | 2020 | 62 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2019 | 109 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2014 | 57 | 0.060 |
Why?
|
| Retinitis Pigmentosa | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hearing Disorders | 1 | 2004 | 2 | 0.060 |
Why?
|
| Self Concept | 1 | 2004 | 42 | 0.060 |
Why?
|
| Mouth, Edentulous | 1 | 2004 | 4 | 0.060 |
Why?
|
| Basal Metabolism | 1 | 2004 | 9 | 0.060 |
Why?
|
| Visual Fields | 1 | 2004 | 27 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2004 | 23 | 0.060 |
Why?
|
| Neck Pain | 1 | 2003 | 6 | 0.060 |
Why?
|
| Shoulder Pain | 1 | 2003 | 10 | 0.060 |
Why?
|
| Prostaglandins | 1 | 2003 | 14 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 22 | 0.060 |
Why?
|
| Hip | 1 | 2003 | 14 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 43 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2003 | 57 | 0.060 |
Why?
|
| Albuminuria | 2 | 2015 | 181 | 0.060 |
Why?
|
| Low Back Pain | 1 | 2003 | 45 | 0.060 |
Why?
|
| Wine | 1 | 2003 | 2 | 0.060 |
Why?
|
| Macaca fascicularis | 2 | 2016 | 397 | 0.060 |
Why?
|
| Dinoprost | 2 | 2013 | 10 | 0.050 |
Why?
|
| Spirometry | 2 | 2014 | 30 | 0.050 |
Why?
|
| Arthralgia | 2 | 2017 | 33 | 0.050 |
Why?
|
| Spinal Puncture | 1 | 2002 | 20 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2013 | 145 | 0.050 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2002 | 6 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 2012 | 70 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 268 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 44 | 0.050 |
Why?
|
| Pain | 1 | 2004 | 287 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2002 | 39 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2009 | 131 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 122 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 161 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2002 | 114 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 155 | 0.050 |
Why?
|
| Ilium | 1 | 2020 | 15 | 0.050 |
Why?
|
| Biomass | 1 | 2020 | 3 | 0.050 |
Why?
|
| Goblet Cells | 1 | 2020 | 5 | 0.050 |
Why?
|
| Mucins | 1 | 2020 | 19 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 17 | 0.050 |
Why?
|
| Dental Plaque Index | 2 | 2013 | 4 | 0.040 |
Why?
|
| Muscle Development | 1 | 2020 | 49 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 319 | 0.040 |
Why?
|
| Cell Wall | 1 | 2019 | 6 | 0.040 |
Why?
|
| Teichoic Acids | 1 | 2019 | 8 | 0.040 |
Why?
|
| Counseling | 1 | 2020 | 97 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2019 | 20 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2020 | 53 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 629 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2019 | 70 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 16 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 260 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2019 | 4 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2019 | 81 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 16 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2019 | 13 | 0.040 |
Why?
|
| Inhalation | 1 | 2018 | 8 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 35 | 0.040 |
Why?
|
| Residence Characteristics | 2 | 2014 | 191 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 16 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2019 | 59 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2018 | 20 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2018 | 31 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 68 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 104 | 0.040 |
Why?
|
| Pedigree | 1 | 2018 | 140 | 0.040 |
Why?
|
| Baltimore | 1 | 2018 | 50 | 0.040 |
Why?
|
| Amidohydrolases | 1 | 2018 | 8 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 284 | 0.040 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2017 | 1 | 0.040 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2017 | 2 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 49 | 0.040 |
Why?
|
| Haplorhini | 1 | 2017 | 66 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2017 | 5 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2017 | 9 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2019 | 180 | 0.040 |
Why?
|
| Ventricular Function, Left | 2 | 2009 | 240 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2017 | 8 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2017 | 56 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2012 | 351 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 93 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 68 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2017 | 40 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 90 | 0.040 |
Why?
|
| Lysine | 1 | 2017 | 23 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2007 | 97 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 94 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2009 | 17 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2017 | 71 | 0.030 |
Why?
|
| Italy | 2 | 2009 | 15 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 21 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 177 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 487 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 116 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2015 | 11 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 106 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 77 | 0.030 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2015 | 11 | 0.030 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2016 | 37 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 60 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 208 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 35 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 482 | 0.030 |
Why?
|
| Ribosomes | 1 | 2015 | 10 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 45 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 185 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 272 | 0.030 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 30 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 189 | 0.030 |
Why?
|
| Mastication | 2 | 2006 | 2 | 0.030 |
Why?
|
| Periodontal Index | 2 | 2005 | 5 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2015 | 9 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2015 | 10 | 0.030 |
Why?
|
| Japan | 1 | 2015 | 17 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 40 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 292 | 0.030 |
Why?
|
| Calcium Citrate | 1 | 2014 | 1 | 0.030 |
Why?
|
| Dehydroepiandrosterone | 1 | 2014 | 10 | 0.030 |
Why?
|
| Rest | 1 | 2015 | 54 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 29 | 0.030 |
Why?
|
| Calcifediol | 1 | 2014 | 7 | 0.030 |
Why?
|
| Acid-Base Imbalance | 1 | 2014 | 2 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 21 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2014 | 22 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 315 | 0.030 |
Why?
|
| Multigene Family | 1 | 2014 | 51 | 0.030 |
Why?
|
| Fish Oils | 1 | 2014 | 36 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2014 | 37 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 124 | 0.030 |
Why?
|
| Range of Motion, Articular | 2 | 2005 | 187 | 0.030 |
Why?
|
| Albumins | 1 | 2014 | 45 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 84 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2014 | 14 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2014 | 55 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 69 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2013 | 31 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 94 | 0.030 |
Why?
|
| Estradiol | 1 | 2014 | 128 | 0.030 |
Why?
|
| Executive Function | 1 | 2014 | 57 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 105 | 0.030 |
Why?
|
| Mandible | 1 | 2013 | 39 | 0.030 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2013 | 2 | 0.030 |
Why?
|
| Glucose | 1 | 2014 | 173 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Glutaredoxins | 1 | 2013 | 9 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 44 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2014 | 187 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2014 | 117 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
| TRPM Cation Channels | 1 | 2013 | 3 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 178 | 0.030 |
Why?
|
| North America | 1 | 2013 | 32 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 2012 | 8 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 1 | 2012 | 12 | 0.030 |
Why?
|
| Steroid Hydroxylases | 1 | 2012 | 2 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 5 | 0.030 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2012 | 9 | 0.030 |
Why?
|
| Velopharyngeal Sphincter | 1 | 2012 | 4 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2012 | 43 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2014 | 122 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2013 | 142 | 0.030 |
Why?
|
| Isotonic Contraction | 1 | 2012 | 8 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 62 | 0.030 |
Why?
|
| Myofibrils | 1 | 2012 | 9 | 0.030 |
Why?
|
| Nerve Net | 1 | 2014 | 123 | 0.030 |
Why?
|
| Income | 1 | 2013 | 61 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 12 | 0.030 |
Why?
|
| Propensity Score | 1 | 2012 | 39 | 0.030 |
Why?
|
| Lysophospholipase | 1 | 2012 | 5 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2012 | 32 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 167 | 0.030 |
Why?
|
| Thromboxane B2 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Vermont | 1 | 2012 | 2 | 0.030 |
Why?
|
| Head | 1 | 2012 | 51 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 11 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2012 | 96 | 0.030 |
Why?
|
| Parkinsonian Disorders | 1 | 2012 | 9 | 0.030 |
Why?
|
| Tremor | 1 | 2012 | 11 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2012 | 94 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 3 | 0.030 |
Why?
|
| Public Opinion | 1 | 2012 | 17 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 135 | 0.030 |
Why?
|
| Prejudice | 1 | 2012 | 50 | 0.030 |
Why?
|
| Myosin Heavy Chains | 1 | 2012 | 89 | 0.030 |
Why?
|
| Developing Countries | 1 | 2012 | 48 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 271 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.020 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 35 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 28 | 0.020 |
Why?
|
| Distance Perception | 1 | 2011 | 3 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 376 | 0.020 |
Why?
|
| Judgment | 1 | 2011 | 10 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 215 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 24 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2016 | 632 | 0.020 |
Why?
|
| Arm | 1 | 2011 | 37 | 0.020 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2010 | 10 | 0.020 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2010 | 10 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 15 | 0.020 |
Why?
|
| Homozygote | 1 | 2010 | 58 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 28 | 0.020 |
Why?
|
| Canada | 1 | 2010 | 56 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 57 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2010 | 66 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 45 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2010 | 24 | 0.020 |
Why?
|
| Netherlands | 1 | 2009 | 22 | 0.020 |
Why?
|
| Angiotensinogen | 1 | 2010 | 59 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2010 | 22 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2009 | 24 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 60 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 28 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 86 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2009 | 48 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2009 | 49 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 48 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 125 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 180 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2009 | 18 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 30 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2009 | 25 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 36 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 85 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 43 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 2008 | 21 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2008 | 31 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2009 | 60 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2002 | 1259 | 0.020 |
Why?
|
| Attention | 1 | 2009 | 83 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 230 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 136 | 0.020 |
Why?
|
| Meat | 1 | 2008 | 15 | 0.020 |
Why?
|
| Asian Americans | 1 | 2008 | 97 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 169 | 0.020 |
Why?
|
| Peptidoglycan | 1 | 2007 | 2 | 0.020 |
Why?
|
| Blood | 1 | 2007 | 10 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 21 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 8 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2008 | 148 | 0.020 |
Why?
|
| Bronchospirometry | 1 | 2007 | 1 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2007 | 6 | 0.020 |
Why?
|
| Optics and Photonics | 1 | 2007 | 7 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2008 | 78 | 0.020 |
Why?
|
| Isometric Contraction | 1 | 2007 | 23 | 0.020 |
Why?
|
| Testosterone | 1 | 2007 | 47 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 32 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 833 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2007 | 73 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 564 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 262 | 0.020 |
Why?
|
| Skin | 1 | 2008 | 210 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2009 | 468 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2009 | 598 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 10 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2006 | 11 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 2005 | 16 | 0.020 |
Why?
|
| Benzoylarginine-2-Naphthylamide | 1 | 2005 | 1 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2005 | 9 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 26 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2005 | 47 | 0.020 |
Why?
|
| Musculoskeletal Physiological Phenomena | 1 | 2005 | 5 | 0.020 |
Why?
|
| Oxygen | 1 | 2006 | 140 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2005 | 66 | 0.020 |
Why?
|
| Arthrography | 1 | 2004 | 11 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 6 | 0.020 |
Why?
|
| Urban Health | 1 | 2004 | 15 | 0.020 |
Why?
|
| Benzothiadiazines | 1 | 2004 | 2 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2004 | 33 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2004 | 57 | 0.020 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2004 | 10 | 0.020 |
Why?
|
| Diuretics | 1 | 2004 | 24 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 48 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2004 | 61 | 0.010 |
Why?
|
| Oral Health | 1 | 2004 | 29 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 11 | 0.010 |
Why?
|
| Computer Graphics | 1 | 2003 | 10 | 0.010 |
Why?
|
| Organizational Policy | 1 | 2003 | 20 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 93 | 0.010 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2003 | 19 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 209 | 0.010 |
Why?
|
| South America | 1 | 2003 | 3 | 0.010 |
Why?
|
| Middle East | 1 | 2003 | 5 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2003 | 64 | 0.010 |
Why?
|
| Asia | 1 | 2003 | 19 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 20 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2004 | 125 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2003 | 103 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 52 | 0.010 |
Why?
|
| Platelet Count | 1 | 2002 | 23 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2003 | 186 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2002 | 26 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 2002 | 16 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2002 | 108 | 0.010 |
Why?
|
| Minnesota | 1 | 2002 | 21 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 17 | 0.010 |
Why?
|
| E-Selectin | 1 | 2002 | 20 | 0.010 |
Why?
|
| Maryland | 1 | 2002 | 28 | 0.010 |
Why?
|
| Mississippi | 1 | 2002 | 27 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 41 | 0.010 |
Why?
|
| Factor VIII | 1 | 2002 | 23 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2002 | 57 | 0.010 |
Why?
|
| Proteinuria | 1 | 2002 | 59 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2002 | 120 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 378 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 1055 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 607 | 0.010 |
Why?
|